Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alogliptin + pioglitazone
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Alogliptin + pioglitazone** is an oral fixed-dose antidiabetic combination of two small molecules: alogliptin, a selective dipeptidyl peptidase-4 inhibitor, and pioglitazone, a thiazolidinedione peroxisome proliferator-activated receptor gamma agonist. DPP-4 inhibition prolongs endogenous incretin activity, supporting glucose-dependent insulin secretion and reducing glucagon secretion, while PPAR-gamma activation improves insulin sensitivity. The combination is marketed for adjunctive treatment of adults with type 2 diabetes mellitus to improve glycemic control alongside diet and exercise. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55))
- Brand names
- IncresyncLiovelNesinaActOseni
- Other names
- alogliptin pioglitazonealogliptin-pioglitazonealogliptin/pioglitazone
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on alogliptin + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alogliptin + pioglitazone.